

# NEXTGEN Rx

COMPOUNDING PHARMACY

3.7.2025

Attention: Compounded Tirzepatide Prescribers,

**Update:** FDA's *Declaratory Order* on 12/19/2024 Re: resolution of drug shortage relating to: Mounjaro® and Zepbound®

On 3/5/2025, the judge presiding over the case OFA v. FDA in regards to compounded Tirzepatide denied the OFA's request for a preliminary injunction. It is likely that the OFA will appeal this decision, however, as of now NextGenRx can only dispense prescriptions for compounded Tirzepatide **until 3/19/2025**.

We have alerted your patients with this information, and have suggested that they "STOCK UP" by ordering their refills by **March 13<sup>th</sup>, 2025**.

Our suggestion for next steps with your patients would be to potentially switch to compounded semaglutide for injection, should they not desire to purchase the brand name: Mounjaro® or Zepbound®. However, that is likely to be a short lived suggestion as the FDA has issued the same order for semaglutide with a date of May 22<sup>nd</sup>, 2025. A long term suggestion would be to switch to a sublingual compound of: Semaglutide 2mg/ml, details in which can be found on our web page at <https://mynextgenrx.com/semaglutide/>. As always, we are here to help please feel free to call or email.

Sincerely,



D.J. Lees Pharm.D.

NextGenRx

[dj.lees@mynextgenrx.com](mailto:dj.lees@mynextgenrx.com)

Scan here to visit to our blog page with updates.

NextGenRx – Tulsa  
4132 E 51<sup>st</sup> St  
Tulsa, OK 74135  
918.578.0031 EXT 2

NextGenRx – Broken Arrow  
811 W. New Orleans St., #101  
Broken Arrow, OK 74011  
918.578.0031 EXT 1